

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

| | | |
|---|--|---|
| 1. Name and Address of Reporting Person* <u>White William Richard</u> (Last) (First) (Middle) C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101 (Street) WATERTOWN MA 02472 (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>Disc Medicine, Inc. [IRON]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below) |
| | 3. Date of Earliest Transaction (Month/Day/Year) 09/03/2024 | |
| 4. If Amendment, Date of Original Filed (Month/Day/Year) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|--------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 09/03/2024 | | M ⁽¹⁾ | | 201 | A | \$9.86 | 201 | D | |
| Common Stock | 09/03/2024 | | M ⁽¹⁾ | | 1,756 | A | \$2.65 | 1,957 | D | |
| Common Stock | 09/03/2024 | | S ⁽¹⁾ | | 1,560 | D | \$49.4302 ⁽²⁾ | 397 | D | |
| Common Stock | 09/03/2024 | | S ⁽¹⁾ | | 337 | D | \$50.2882 ⁽³⁾ | 60 | D | |
| Common Stock | 09/03/2024 | | S ⁽¹⁾ | | 50 | D | \$51.544 ⁽⁴⁾ | 10 | D | |
| Common Stock | 09/03/2024 | | S ⁽¹⁾ | | 10 | D | \$52.28 | 0 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|--|-------|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | | Title |
| Stock Option (Right to Buy) | \$9.86 | 09/03/2024 | | M ⁽¹⁾ | | | 201 | (5) | 09/13/2031 | Common Stock | 201 | \$0.00 | 2,407 | D | |
| Stock Option (Right to Buy) | \$2.65 | 09/03/2024 | | M ⁽¹⁾ | | | 1,756 | (6) | 11/26/2030 | Common Stock | 1,756 | \$0.00 | 1,756 | D | |

Explanation of Responses:

- The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$48.975 to \$49.965, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$49.975 to \$50.905, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$51.135 to \$51.80, inclusive.
- The shares underlying this option vest in 48 equal monthly installments following September 1, 2021, subject to the Reporting Person's continued service on each such vesting date.
- The shares underlying this option vest in 16 equal quarterly installments following November 27, 2020, subject to the Reporting Person's continued service on each such vesting date.

By: /s/ Rahul Khara, as Attorney-in-Fact 09/05/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

